Legend Biotech Reports Promising Safety Data for First-in-Class Cell Therapy in B-Cell Lymphoma
核心洞察
Legend Biotech, an associate company of GenScript, reported positive phase one safety data for a potential first-in-class cell therapy (搜索) treating relapsed or refractory B-cell non-Hodgkin lymphoma (搜索).
The trial enrolled 12 patients who experienced no toxicities, no serious adverse events, and no deaths during the early-stage safety evaluation.
The promising results will be presented as a late-breaking oral presentation at the European Hematology Association 2026 Congress in Stockholm.
Legend Biotech, a Nasdaq Global Select Market-listed company and associate of GenScript Biotech Holdings (搜索), has disclosed promising early clinical safety data for a potential first-in-class cell therapy (搜索) targeting cancer (搜索) patients. The announcement drove GenScript shares to surge as much as 29 percent in Hong Kong trading before closing 10.54 percent higher at HK$13.42.
Phase One Trial Results
The phase one trial, designed primarily to evaluate therapy safety and gather early efficacy signals in humans, enrolled 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma (搜索). These patients had cancer (搜索) that either returned after prior treatment or stopped responding to existing therapies altogether.
According to the company's statement published on June 2, all 12 patients in the trial experienced no toxicities, no serious adverse events, and no deaths. This safety profile represents a significant milestone for the experimental cell therapy (搜索) as it advances through clinical development.
Clinical Presentation and Timeline
The phase one data set will be featured as a late-breaking oral presentation at the European Hematology Association 2026 Congress, scheduled to take place from June 11 to 14 in Stockholm, Sweden. This prestigious platform underscores the potential significance of the clinical findings within the hematology community.
China's Growing Pharmaceutical Presence
The positive results highlight China's expanding role in global pharmaceutical innovation. According to a January report from consultancy McKinsey & Company (搜索), China now accounts for about one-third of the global early-stage drug pipeline. This substantial contribution reflects the country's increasing capabilities in drug discovery and development.
Over the past two years, a growing number of Chinese biotech firms have out-licensed early-stage drug candidates to US counterparts, demonstrating the international recognition of Chinese pharmaceutical research quality. However, the country's ascent in the global pharmaceutical value chain has also raised concerns among US lawmakers, reflecting broader geopolitical tensions in the biotechnology sector.